// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

large scale tumor mutational burden analysis of pediatric tumors provides a diagnostic tool for germline predisposition and reveals novel candidates for immune checkpoint inhibition

Brittany B. Campbell - Society for Neuro-Oncology (SNO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Location and histology dictate the likelihood of molecular events in pediatric low-grade glioma

Michal Zapotocky - Society for Neuro-Oncology (SNO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Molecular alterations predict response to chemotherapy and outcome of pediatric low-grade glioma

Scott Ryall - Society for Neuro-Oncology (SNO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Transcriptional regulation of the homeobox genes CRX and OTX2 - implications for medulloblastoma group 3

Maryam Hejazi - Society for Neuro-Oncology (SNO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Metabolic syndrome (MetS) after platinum-based chemotherapy (CHEM): A multicenter study of North American testicular cancer survivors (TCS).

Mohammad Issam Abu Zaid - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

sICAM-1

Reducing the burden of patient reporting of physical function in the chronic care of cancer survivors through a branching logic electronic symptom survey (BLESS).

Elizabeth Hall - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Total and cancer-attributable phase- based costs for childhood cancer care: A population-based study in British Columbia, Canada.

Mary L McBride - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Total and cancer-attributable phase-based costs for adolescent cancer care: A population–based study in British Columbia, Canada.

Mary L McBride - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Treatment-induced hypoxia attenuates enzalutamide response and promotes resistance in pre-clinical models of prostate cancer

P.J.Maxwell - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Identifying critical data elements for a provincial transition plan from a primary care perspective.

Stacey Hunter - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Integrated molecular signatures of TERT promoter deregulation predict disease outcomes in non-muscle invasive bladder cancer

R.Leao - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Clinical dysregulation of DNA repair by the polynucleotide kinase/phosphatase-XRCC4-DNA ligase IV in neurological disease

D.Aceytuno - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Comparative study of the perceptions of continuity of care of CRC survivors transitioned to primary care.

Jeffrey James Sisler - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Barriers to care in two differing models of follow-up for long-term childhood cancer survivors.

Brooke Russell - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

Prevalence of sarcopenia and predictors of body composition among women with early-stage breast cancer.

Elizabeth (Cespedes) Feliciano - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Implementation of an exercise behavior change clinic for men with prostate cancer: Baseline results.

Sarah Weller - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Awareness among patients with cancer of the harms of continued smoking.

Lawson Eng - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Development of a Decision Aid for Young Canadians Diagnosed with Breast Cancer who are at Risk of Infertility Following Cancer Treatment.

Brittany Speller - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Evaluation of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs)

A.Prawira - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

EGFR copy number aberrations detected in cfDNA from advanced NSCLC patients

G.M.O'Kane - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved